The clinical effects of treatment with -adrenoceptor (-AR) agonists and antagonists in heart failure vary with duration of therapy, as do the effects of -AR agonists in asthma. Therefore, we hypothesized that chronic effects of ''-blockers'' in asthma may differ from those observed acutely. We tested this hypothesis in an antigen (ovalbumin)-driven murine model of asthma. Airway resistance responses (R aw) to the muscarinic agonist methacholine were measured by using the forced oscillation technique. In comparison with nontreated asthmatic mice, we observed that: (i) The -AR antagonists nadolol or carvedilol, given as a single i.v. injection (acute treatment) 15 min before methacholine, increased methacholine-elicited peak R aw values by 33.7% and 67.7% (P < 0.05), respectively; when either drug was administered for 28 days (chronic treatment), the peak R aw values were decreased by 43% (P < 0.05) and 22.9% (P < 0.05), respectively. (ii) Chronic treatment with nadolol or carvedilol significantly increased -AR densities in lung membranes by 719% and 828%, respectively. (iii) Alprenolol, a -blocker with partial agonist properties at -ARs, behaved as a -AR agonist, and acutely reduced peak Raw value by 75.7% (P < 0.05); chronically, it did not alter Raw. (iv) Salbutamol, a -AR partial agonist, acutely decreased peak R aw by 41.1%; chronically, it did not alter Raw. (v) None of the -blockers produced significant changes in eosinophil number recovered in bronchoalveolar lavage. These results suggest that -AR agonists and -blockers with inverse agonist properties may exert reciprocating effects on cellular signaling dependent on duration of administration.-blockers ͉ sympathomimetics ͉ airway resistance ͉ inverse agonist